Avignon, May 16, 2012 - NATUREX, the world leader in specialty plant-based natural ingredients, informs its shareholders about the availability of the documentation relating to the Ordinary and Extraordinary General Meeting on June 8, 2012.
The shareholders of the Company are convened to the Ordinary and Extraordinary General Meeting:
Friday June 8, 2012 at 9:00am
NYSE EURONEXT - Auditorium Cambon
39 rue Cambon
A notice including the agenda and the final text of the resolutions to be proposed to shareholders for approval has been published in the Official Bulletin (BALO - Bulletin des Annonces Légales Obligatoires) and in a legal newspaper on May 16, 2012. A preliminary notice was published in the Official Bulletin in May 4, 2012.
The documents provided by Article R.225-83 of the Commercial Law (Code de Commerce) are made available to shareholders after the convening of the meeting in accordance with the applicable regulations.
All information on how to participate and vote at this General Meeting and a booklet including the documents specified in Article R.225-81 of the Commercial Law (Code de Commerce) are available on NATUREX website: www.naturex.fr (Investors section> Documents> General meetings).
2011 Reference Document filed in April 26, 2012 with the French Financial Markets Authority
(AMF - Autorité des Marchés Financiers) may also be viewed on the Company's website (an English translation will be soon available), including the annual financial report 2011, under Article L 451-1 -2 of the Monetary and Financial Code Code monétaire et financier), the report on the organization of the board and internal control procedures and the statement concerning fees paid to auditors.
Receive free of charge by e-mail all financial information concerning NATUREX by registering on: www.naturex.com
Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps)
|Number of shares comprising the capital: 7,711,076
6,953,768 ordinary shares (ISIN FR0000054694)
757,308 preferred shares (ISIN FR0010833251)
Naturex is a component of the CAC Small and Gaïa indexes.
Naturex is eligible for "long only" Deferred Settlement Service (SRD).
Naturex has implemented a Sponsored Level I American Depositary Receipt (ADR) program,
which trades on over-the-counter market in the United States under symbol NTUXY.
TICKER: NRX - Reuters : NATU.PA - Bloomberg : NRX:FP - DR Symbol: NTUXY
NATUREX is a global leader in specialty plant-based natural ingredients.
The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
NATUREX's head office is based in Avignon, France. The company employs more than 1,200 people with high-performance manufacturing operations across 16 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland, Poland), as well as in Morocco, the United States, Brazil, Australia and India. It also has a global presence through a dedicated network of sales offices in 21 countries (France, Italy, Spain, Morocco, the United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil, Mexico and India).
President and Chief Executive Officer
Tel.: +33 (0)4 90 23 96 89
Vice-President and Chief Financial Officer
Tel.: +33 (0)4 90 23 96 89
Tel.: +33 (0)4 90 23 78 28
Anne Catherine Bonjour
Actus Finance Press Relations
Tel.: +33 (0)1 53 67 36 93
Communiqués de mise à disposition de documents :
- Modalités de mise à disposition des documents préparatoires à l'AG Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-27931-12.05.16-general-meeting-information-available.pdf © Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|NATUREX||Euronext Paris||85.00 (c)||-1.27%||2 632|